[Clinical trial on safety of inactivated split influenza virus vaccine, Anflu in 2007-2008].
OBJECTIVE
To review the safety of the inactivated split influenza vaccine, Anflu in a large scale population.


METHODS
Selecting 14 districts national wide to inject the inactivated split influenza vaccines according schedules among infants, children, youths, adults and elder respectively. All volunteers were observed for AEFI after 7 days vaccinated.


RESULTS
A total of 2794 volunteers aged 6 months to 90 years were enrolled in trials. The overall rate of adverse events was 6.6%.most adverse was mild reaction. Severe, infrequent or new adverse events were not reported. The rate of local reactions was 2.1%. The rate of local pain was 1.7%. The rate of systematic adverse events was 5.0%, fever took up 3.8%.


CONCLUSIONS
The inactivated split influenza vaccine, Anflu was safe.
Wang
Xu
X
Sinovac Biotech Co., Ltd, Beijing 100085, China.
Liu
Yan
Y
Zhao
Yan-Wei
YW
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002675:Child, Preschool; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D006801:Humans; D007223:Infant; D007252:Influenza Vaccines / Q000008:administration & dosage* / Q000009:adverse effects; D007251:Influenza, Human / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D014611:Vaccination; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000009:adverse effects; D055815:Young Adult
D007252:Influenza Vaccines; D015164:Vaccines, Inactivated